DARE
Daré Bioscience, Inc.
Price Chart
Latest Quote
$2.17
+0.09 (+4.33%)
Current Price
| Previous Close | $2.08 |
| Open | $2.08 |
| Day High | $2.17 |
| Day Low | $2.05 |
| Volume | 145,142 |
Stock Information
| Shares Outstanding | 14.98M |
| Total Debt | $7.18M |
| Cash Equivalents | $18.52M |
| Revenue | $1.16M |
| Net Income | $-12.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $32.51M |
| EPS (TTM) | $-0.92 |
| Exchange | NCM |
📊 Comprehensive Analysis
Company Data
| Enterprise Value | $21.17M |
| Sales | $1.16M |
| Income | $-12.02M |
| Book/sh | $0.05 |
| Cash/sh | $1.24 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 0.89 |
| Current Ratio | 1.03 |
| Debt/Eq | 978.02 |
Returns & Margins
| ROA | -32.21% |
| Gross Margin | 194.95% |
| Operating Margin | -1967.07% |
Ownership
| Insider Ownership | 8.08% |
| Institutional Ownership | 8.39% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.25 |
| P/S | 28.09 |
| P/B | 43.40 |
Analyst Data
| Recommendation | none |
| Target Price | $9.67 |
Technical Indicators
| SMA20 | $2.13 |
| SMA50 | $2.30 |
| SMA200 | $1.99 |
| RSI | 47.32 |
| ATR | 0.1518 |
| Shares Float | 13.73M |
| Short Float | 5.54% |
| Short Ratio | 1.04 |
| Volatility | 1.02 |
| Rel Volume | 0.84 |
Performance History
| Week | +6.90% |
| Month | -3.56% |
| Quarter | +66.92% |
| 6 Months | -3.98% |
| YTD | +11.28% |
| Year | -24.78% |
| 3 Years | -81.36% |
| 5 Years | -86.99% |
| 10 Years | -99.15% |
Stock Score:
⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature
Sign up for free to view detailed scoring breakdown — premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.17 | 179,600 |
| 2026-06-17 | $2.08 | 133,300 |
| 2026-06-16 | $2.11 | 365,200 |
| 2026-06-15 | $1.98 | 221,800 |
| 2026-06-12 | $2.02 | 92,800 |
| 2026-06-11 | $2.03 | 132,400 |
| 2026-06-10 | $2.00 | 157,900 |
| 2026-06-09 | $1.92 | 117,900 |
| 2026-06-08 | $1.85 | 171,500 |
| 2026-06-05 | $1.88 | 450,700 |
| 2026-06-04 | $2.18 | 170,800 |
| 2026-06-03 | $2.05 | 223,900 |
| 2026-06-02 | $2.14 | 89,000 |
| 2026-06-01 | $2.19 | 177,300 |
| 2026-05-29 | $2.23 | 170,200 |
| 2026-05-28 | $2.28 | 289,400 |
| 2026-05-27 | $2.33 | 255,900 |
| 2026-05-26 | $2.34 | 232,900 |
| 2026-05-22 | $2.37 | 435,700 |
| 2026-05-21 | $2.41 | 187,300 |
| 2026-05-20 | $2.33 | 309,000 |
| 2026-05-19 | $2.25 | 554,100 |
About Daré Bioscience, Inc.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
📰 Latest News
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...
GuruFocus.com • 2026-05-15T05:03:13ZOrchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Zacks • 2026-05-12T21:40:05Z
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
Zacks • 2026-03-26T21:20:01Z
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Zacks • 2026-03-09T12:25:02Z
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Zacks • 2026-03-02T13:20:02Z
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth
Simply Wall St. • 2026-01-20T10:48:44Z
Daré Bioscience, Inc. Q3 2025 Earnings Call Summary
Moby • 2025-11-14T13:30:00Z
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...
GuruFocus.com • 2025-11-14T05:02:50Z
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Zacks • 2025-11-13T22:10:02Z
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates
Zacks • 2025-11-12T22:30:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $295,799 | - | - | - |
| Cost Of Revenue | $295,799 | - | - | - |
| Total Revenue | $1,030,193 | $9,784 | $2,807,885 | $10,000,000 |
| Operating Revenue | $1,030,193 | $9,784 | $2,807,885 | $10,000,000 |
| Expenses | ||||
| Total Expenses | $14,582,527 | $23,461,269 | $33,747,765 | $41,385,488 |
| Other Income Expense | $153,060 | $19,397,886 | $778,489 | $437,750 |
| Other Non Operating Income Expenses | $153,060 | $-981,490 | $778,489 | $437,750 |
| Operating Expense | $14,286,728 | $23,461,269 | $33,747,765 | $41,385,488 |
| General And Administrative Expense | $8,763,376 | $9,156,061 | $12,109,691 | $11,243,271 |
| Other Operating Expenses | - | $100,000 | $100,000 | $100,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Normalized Income | $-13,399,274 | $-24,432,975 | $-30,161,391 | $-30,947,738 |
| Net Income From Continuing And Discontinued Operation | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Total Operating Income As Reported | $-13,552,334 | $-23,451,485 | $-30,939,880 | $-31,385,488 |
| Net Income Common Stockholders | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Net Income | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Net Income Including Noncontrolling Interests | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Net Income Continuous Operations | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Pretax Income | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Special Income Charges | $0 | $20,379,376 | $0 | $0 |
| Operating Income | $-13,552,334 | $-23,451,485 | $-30,939,880 | $-31,385,488 |
| Gross Profit | $734,394 | - | - | - |
| Per Share | ||||
| Diluted EPS | $-1.20 | $-0.48 | $-4.15 | $-4.44 |
| Basic EPS | $-1.20 | $-0.48 | $-4.15 | $-4.44 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,917,848 | $-43,788,536 | $-30,901,517 | $-31,361,286 |
| Total Unusual Items | $0 | $20,379,376 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $20,379,376 | $0 | $0 |
| Reconciled Depreciation | $1,634,486 | $42,325 | $38,363 | $24,202 |
| EBITDA (Bullshit earnings) | $-11,917,848 | $-23,409,160 | $-30,901,517 | $-31,361,286 |
| EBIT | $-13,552,334 | $-23,451,485 | $-30,939,880 | $-31,385,488 |
| Diluted Average Shares | $11,178,752 | $8,497,459 | $7,275,308 | $7,047,650 |
| Basic Average Shares | $11,178,752 | $8,497,459 | $7,275,308 | $7,047,650 |
| Diluted NI Availto Com Stockholders | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Gain On Sale Of Ppe | $0 | $20,379,376 | $0 | - |
| Research And Development | $5,523,352 | $14,305,208 | $21,538,074 | $30,042,217 |
| Selling General And Administration | $8,763,376 | $9,156,061 | $12,109,691 | $11,243,271 |
| Other Gand A | $8,763,376 | $9,156,061 | $12,109,691 | $11,243,271 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Total Assets | $32,474,563 | $22,101,131 | $21,282,215 | $43,826,383 |
| Total Non Current Assets | $5,410,684 | $3,653,268 | $3,738,676 | $787,630 |
| Other Non Current Assets | $1,009,439 | $1,110,594 | $599,594 | $254,295 |
| Current Assets | $27,063,879 | $18,447,863 | $17,543,539 | $43,038,753 |
| Other Current Assets | $65,405 | - | - | - |
| Current Deferred Assets | $321,686 | $0 | - | - |
| Prepaid Assets | $1,392,371 | $2,519,707 | $6,118,272 | $6,665,988 |
| Receivables | $573,061 | $229,982 | $949,211 | $1,703,160 |
| Other Receivables | $573,061 | $229,982 | $949,211 | $1,703,160 |
| Cash Cash Equivalents And Short Term Investments | $24,711,356 | $15,698,174 | $10,476,056 | $34,669,605 |
| Cash And Cash Equivalents | $24,711,356 | $15,698,174 | $10,476,056 | $34,669,605 |
| Non Current Prepaid Assets | - | $12,027 | $1,163,477 | $10,502 |
| Non Current Deferred Assets | - | - | - | $139,203 |
| Debt | ||||
| Total Debt | $2,656,019 | $1,303,021 | $1,404,469 | $488,737 |
| Long Term Debt And Capital Lease Obligation | $559,365 | $754,383 | $935,743 | $90,346 |
| Current Debt And Capital Lease Obligation | $2,096,654 | $548,638 | $468,726 | $398,391 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,631,929 | $28,113,220 | $26,329,855 | $32,714,273 |
| Total Non Current Liabilities Net Minority Interest | $5,946,242 | $6,500,153 | $5,849,419 | $1,090,346 |
| Other Non Current Liabilities | $5,386,877 | $4,745,770 | $3,913,676 | - |
| Non Current Deferred Liabilities | $0 | $1,000,000 | $1,000,000 | $1,000,000 |
| Current Liabilities | $23,685,687 | $21,613,067 | $20,480,436 | $31,623,927 |
| Other Current Liabilities | $11,711 | $4,054 | - | - |
| Current Deferred Liabilities | $19,651,452 | $16,561,625 | $13,737,154 | $18,303,567 |
| Payables And Accrued Expenses | $1,915,609 | $3,693,138 | $5,469,144 | $11,201,468 |
| Payables | $1,383,207 | $1,705,460 | $3,659,243 | $2,027,953 |
| Other Payable | $182,521 | $249,628 | $273,692 | - |
| Accounts Payable | $1,200,686 | $1,455,832 | $3,385,551 | $2,027,953 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Total Equity Gross Minority Interest | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Stockholders Equity | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Gains Losses Not Affecting Retained Earnings | $-421,623 | $-428,809 | $-360,896 | $-351,311 |
| Other Equity Adjustments | $-421,623 | $-428,809 | $-360,896 | $-351,311 |
| Retained Earnings | $-188,688,904 | $-175,289,630 | $-171,236,031 | $-141,074,640 |
| Other | ||||
| Ordinary Shares Number | $14,499,502 | $8,700,386 | $8,331,160 | $7,068,790 |
| Share Issued | $14,499,502 | $8,700,386 | $8,331,160 | $7,068,790 |
| Tangible Book Value | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Invested Capital | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Working Capital | $3,378,192 | $-3,165,204 | $-2,936,897 | $11,414,826 |
| Capital Lease Obligations | $2,656,019 | $1,303,021 | $1,404,469 | $488,737 |
| Total Capitalization | $2,842,634 | $-6,012,089 | $-5,047,640 | $11,112,110 |
| Additional Paid In Capital | $191,951,711 | $169,705,480 | $166,548,454 | $152,529,579 |
| Capital Stock | $1,450 | $870 | $833 | $8,482 |
| Common Stock | $1,450 | $870 | $833 | $8,482 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $1,000,000 | $1,000,000 | $1,000,000 |
| Long Term Capital Lease Obligation | $559,365 | $754,383 | $935,743 | $90,346 |
| Current Deferred Revenue | $19,651,452 | $16,561,625 | $13,737,154 | $18,303,567 |
| Current Capital Lease Obligation | $2,096,654 | $548,638 | $468,726 | $398,391 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,261 | $805,612 | $805,412 | $1,720,501 |
| Current Accrued Expenses | $532,402 | $1,987,678 | $1,809,901 | $9,173,515 |
| Net PPE | $4,401,245 | $2,542,674 | $1,975,605 | $522,833 |
| Accumulated Depreciation | $-338,013 | $-175,894 | $-145,702 | - |
| Gross PPE | $4,739,258 | $2,718,568 | $2,121,307 | $522,833 |
| Leases | $40,284 | $40,284 | $42,188 | - |
| Construction In Progress | $0 | $1,229,165 | $600,000 | - |
| Other Properties | $4,651,047 | $1,411,880 | $1,427,141 | $522,833 |
| Machinery Furniture Equipment | $47,927 | $37,239 | $51,978 | - |
| Properties | $0 | $0 | $0 | - |
| Buildings And Improvements | - | $1,206,942 | $1,319,630 | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,271,148 | $4,900,509 | $-39,486,084 | $-18,151,498 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,885,870 | $5,473,555 | $-38,856,654 | $-18,088,429 |
| Cash Flow From Continuing Operating Activities | $-9,885,870 | $5,473,555 | $-38,856,654 | $-18,088,429 |
| Operating Gains Losses | $-6,298 | $600,202 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-385,278 | $-573,046 | $-629,430 | $-63,069 |
| Investing Cash Flow | $-385,278 | $-573,046 | $-629,430 | $-63,069 |
| Cash Flow From Continuing Investing Activities | $-385,278 | $-573,046 | $-629,430 | $-63,069 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $20,930,126 | $453,579 | $9,346,656 | $1,218,750 |
| Financing Cash Flow | $19,277,144 | $354,522 | $15,637,120 | $1,343,354 |
| Cash Flow From Continuing Financing Activities | $19,277,144 | $354,522 | $15,637,120 | $1,343,354 |
| Net Other Financing Charges | $-321,686 | $-81,497 | $4,723,899 | - |
| Net Common Stock Issuance | $20,930,126 | $453,579 | $9,346,656 | $1,218,750 |
| Common Stock Issuance | $20,930,126 | $453,579 | $9,346,656 | $1,218,750 |
| Other | ||||
| Repayment Of Debt | $-1,818,017 | $-579,223 | $-333,985 | $0 |
| Issuance Of Debt | $486,721 | $561,663 | $601,174 | $0 |
| End Cash Position | $25,011,356 | $15,998,174 | $10,811,056 | $34,669,605 |
| Beginning Cash Position | $15,998,174 | $10,811,056 | $34,669,605 | $51,674,087 |
| Effect Of Exchange Rate Changes | $7,186 | $-67,913 | $-9,585 | $-196,338 |
| Changes In Cash | $9,005,996 | $5,255,031 | $-23,848,964 | $-16,808,144 |
| Net Issuance Payments Of Debt | $-1,331,296 | $-17,560 | $267,189 | $0 |
| Net Long Term Debt Issuance | $-1,331,296 | $-17,560 | $267,189 | $0 |
| Long Term Debt Payments | $-1,818,017 | $-579,223 | $-333,985 | $0 |
| Long Term Debt Issuance | $486,721 | $561,663 | $601,174 | $0 |
| Net PPE Purchase And Sale | $-385,278 | $-573,046 | $-629,430 | $-63,069 |
| Purchase Of PPE | $-385,278 | $-573,046 | $-629,430 | $-63,069 |
| Change In Working Capital | $789,257 | $5,893,050 | $-10,426,893 | $10,699,658 |
| Change In Other Working Capital | $3,089,828 | $2,824,471 | $-4,566,413 | $7,760,584 |
| Change In Other Current Liabilities | $-548,638 | $-459,763 | $915,732 | - |
| Change In Other Current Assets | $-144,128 | $45,562 | $-10,300 | $3,650 |
| Change In Payables And Accrued Expense | $-1,933,212 | $-1,237,428 | $-6,914,600 | $7,682,642 |
| Change In Accrued Expense | $-1,678,066 | $692,289 | $-8,272,201 | $7,757,774 |
| Change In Interest Payable | $572,561 | $520,816 | $0 | - |
| Change In Payable | $-255,146 | $-1,929,717 | $1,357,601 | $-75,132 |
| Change In Account Payable | $-255,146 | $-1,929,717 | $1,357,601 | $-75,132 |
| Change In Prepaid Assets | $668,486 | $4,000,979 | $-605,260 | $-4,189,376 |
| Change In Receivables | $-343,079 | $719,229 | $753,948 | $-557,842 |
| Changes In Account Receivables | $-12,053 | $0 | - | - |
| Other Non Cash Items | $-400,603 | $788,321 | $-837,417 | $-23,062 |
| Stock Based Compensation | $1,496,562 | $2,203,256 | $2,530,684 | $2,158,511 |
| Depreciation Amortization Depletion | $1,634,486 | $42,325 | $38,363 | $24,202 |
| Depreciation And Amortization | $1,634,486 | $42,325 | $38,363 | $24,202 |
| Depreciation | $1,634,486 | $42,325 | $38,363 | $24,202 |
| Gain Loss On Sale Of PPE | $-6,298 | $600,202 | $0 | - |
| Net Income From Continuing Operations | $-13,399,274 | $-4,053,599 | $-30,161,391 | $-30,947,738 |
| Proceeds From Stock Option Exercised | - | $0 | $1,299,376 | $124,604 |
Fetched: 2026-06-19